Tesamorelin
Stabilized GHRH analog with extended activity and strong GH pulse.
Tap a strength to switch — price, image & stock update automatically
Key Benefits
FDA-approved to reduce visceral adipose tissue by 15–18% over 26 weeks, with selective action on deep abdominal fat
produces 2–3× greater IGF-1 increase than Sermorelin at equivalent doses due to its extended 26–38 minute half-life
2016 study in older adults showed significant improvement in executive function and memory after 20 weeks of therapy
trans-3-hexenoic acid modification protects against enzymatic breakdown, enabling once-daily dosing with sustained GH pulses
Active Signaling Pathway
Tesamorelin's trans-3-hexenoic acid modification extends its half-life to 26–38 minutes, producing stronger and more sustained GH pulses than native GHRH. Particularly effective at reducing visceral adipose tissue.
Investigated Pathways
Proposed Mechanism
Tesamorelin is GHRH(1-44) with a trans-3-hexenoic acid group conjugated to the N-terminus. This modification protects against dipeptidyl peptidase IV (DPP-IV) cleavage, extending the half-life from ~7 minutes (native GHRH) to ~26–38 minutes. It binds GHRH receptors on pituitary somatotrophs with high affinity, producing robust, physiologically pulsatile GH release.
Research Highlights
- FDA-approved (Egrifta, 2010) for HIV-associated lipodystrophy — reduces visceral adipose tissue by 15–18% over 26 weeks
- MAINTAIN trial: sustained visceral fat reduction with continued therapy; fat returns upon discontinuation
- 2016 study in healthy older adults: significant improvement in cognitive function (executive function, memory) after 20 weeks
- Produces 2–3× greater IGF-1 elevation compared to Sermorelin at equivalent doses due to extended half-life
Human observational or open-label study data exists. Controlled trial data may be limited. Not a treatment recommendation.
For laboratory research only
All Research Systems →Human Body
Research begins at the whole-organism level — studying systemic metabolic markers, energy expenditure, and physiological response to peptide intervention.
For laboratory research and educational purposes only.
Human Body
Research begins at the whole-organism level — studying systemic metabolic markers, energy expenditure, and physiological response to peptide intervention.
For laboratory research and educational purposes only.
For research use only — not for human consumption. No treatment claims.
Full Research Hub →Recommended Stacks
Tesamorelin is a key compound in these curated research stacks. Pair it with synergistic peptides for enhanced outcomes.
Lean Body Recomposition
Build lean muscle while burning fat simultaneously — the holy grail of body composition research.
How long will one vial last?
Based on standard research protocols, here's exactly what to expect from a single 20mg vial — and when to plan your next order.
Vial supply estimate is based on standard research protocol volumes. Actual duration will vary based on your specific protocol design.
Scientific Background
Mechanism of Action
Tesamorelin is GHRH(1-44) with a trans-3-hexenoic acid group conjugated to the N-terminus. This modification protects against dipeptidyl peptidase IV (DPP-IV) cleavage, extending the half-life from ~7 minutes (native GHRH) to ~26–38 minutes. It binds GHRH receptors on pituitary somatotrophs with high affinity, producing robust, physiologically pulsatile GH release.
Clinical Context
Tesamorelin has the strongest clinical evidence base of any GHRH analog, with FDA approval and multiple Phase 3 trials. Its selective action on visceral fat (vs. subcutaneous fat) makes it uniquely valuable for metabolic research. The cognitive benefits observed in aging models suggest potential applications in neurodegeneration research.
Research Highlights
- FDA-approved (Egrifta, 2010) for HIV-associated lipodystrophy — reduces visceral adipose tissue by 15–18% over 26 weeks
- MAINTAIN trial: sustained visceral fat reduction with continued therapy; fat returns upon discontinuation
- 2016 study in healthy older adults: significant improvement in cognitive function (executive function, memory) after 20 weeks
- Produces 2–3× greater IGF-1 elevation compared to Sermorelin at equivalent doses due to extended half-life
Storage & Reconstitution
Key Studies
Effects of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients (MAINTAIN trial)
Falutz J et al.
Tesamorelin reduced visceral adipose tissue by 15–18% over 26 weeks in HIV-associated lipodystrophy — the basis for FDA approval.
PubMed →Tesamorelin reduces visceral fat and liver fat in HIV-infected patients
Stanley TL et al.
Tesamorelin selectively reduced visceral fat while preserving subcutaneous fat, with significant IGF-1 elevation.
PubMed →Long-term safety and efficacy of tesamorelin in HIV-associated lipodystrophy
Falutz J et al.
Two-year data confirmed sustained visceral fat reduction with continued tesamorelin; fat returned upon discontinuation.
PubMed →Pharmacokinetics
Bioavailability indicates how much of the compound reaches systemic circulation. Peak plasma is when blood levels are highest. Half-life determines dosing frequency — compounds with short half-lives require more frequent dosing to maintain therapeutic levels.
The volume of distribution reflects how widely the compound distributes into tissues. A higher Vd means the compound concentrates in tissues rather than staying in plasma.
Receptor Binding Profile
Robust pulsatile GH release from pituitary somatotrophs via cAMP cascade
2–3× greater IGF-1 elevation vs Sermorelin at equivalent doses
Downstream hepatic IGF-1 production; selective visceral fat reduction
Side Effects & Adverse Events
- Injection site reactions (25%)
- Fluid retention
- Joint pain (arthralgia)
- Glucose intolerance
- Carpal tunnel syndrome symptoms
- Peripheral edema
- Glucose elevation (monitor in diabetes)
- Elevated IGF-1 (monitor levels)
Contraindications & Interactions
Synergistic Compounds
GHRH + GHRP dual-signal mechanism amplifies GH pulse — tesamorelin's extended half-life provides sustained GHRH stimulation.
Tesamorelin 1 mg + Ipamorelin 200 mcg, both SubQ, once daily.
View Compound →Tesamorelin targets visceral fat via GH/IGF-1 axis while AOD-9604 directly activates adipocyte lipolysis — complementary fat loss mechanisms.
Tesamorelin 1 mg AM + AOD-9604 300 mcg fasted, both SubQ.
View Compound →Transparent Global Sourcing
Manufactured
Sourced through our manufacturing partner in China
Independent Testing
Analytical reports available from Janoshik Analytical
Batch Verification
Batch-specific COAs with online verification via janoshik.com
US Fulfillment
Orders fulfilled from the United States